A Phase III trial of Verdiperstat for the Treatment of Multiple-System-Atrophy (MSA)
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Verdiperstat (Primary)
- Indications Multiple system atrophy
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 23 Jan 2019 According to a Biohaven Pharmaceutical media release, the company expects to initiate this trial in the third quarter of 2019.
- 02 Dec 2018 New trial record
- 14 Nov 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company plans to initiate this trial in 2019 for the treatment of MSA.